March 23, 2021 09:46 AM EDTUpdated 11:18 AM

'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials

Nicole DeFeudis

Editor

Moderna emerged as an early leader in the race for a vaccine to stop Covid-19 in its tracks. The Cambridge, Massachusetts-based biotech bounded through development …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials

Nicole DeFeudis

Editor

Sign up to read this article for free.

Vice President, Biology & Translational Research

Gondolabio

Palo Alto, CA, USA

Sanofi to pay $125M upfront for two immunology drugs from little-known biotech

US drugs rely heavily on ingredients made overseas, new report shows

Exclusive: VelaVigo inks another US biotech deal as China drug development scene booms

Sarepta loses CMO to RNA editing upstart; Another wave of personnel moves at Dyne

Biotech seed rounds sink to lowest level in years as industry slump drags on

New York-based partnership sets the standard for expanding clinical trial access for underserved and diverse ...

'Part of re­cov­ery is aware­ness': Pan­dem­ic casts harsh spot­light on in­dus­try-wide lack of di­ver­si­ty in clin­i­cal tri­als

Editor

Sign up to read this article for free.

Gondolabio

Palo Alto, CA, USA

'Part of recovery is awareness': Pandemic casts harsh spotlight on industry-wide lack of diversity in clinical trials